Startup | May 09, 2022
InxMed raises US $ 15 million in Series B+ financing
The plan is to advance innovative therapies to drug-resistant cancers
The plan is to advance innovative therapies to drug-resistant cancers
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Upon closing, the Quakertown business will become an independent company called Microsize
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The research was supported by the BGU Coronavirus Challenge and the Israeli Ministry of Health.
This partnership expands DNA Script’s footprint and provides sales and support for the SYNTAX System DNA printer in labs in India
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
At an affordable price, a researcher can process fresh samples of 10,000 cells immediately with a stable stopping point within two hours, simplifying sample management at the laboratory and limiting transcriptional changes
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
Subscribe To Our Newsletter & Stay Updated
